AR036813A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
AR036813A1
AR036813A1 ARP020103852A ARP020103852A AR036813A1 AR 036813 A1 AR036813 A1 AR 036813A1 AR P020103852 A ARP020103852 A AR P020103852A AR P020103852 A ARP020103852 A AR P020103852A AR 036813 A1 AR036813 A1 AR 036813A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
mycophenolic acid
mycophenolate salt
dose form
solid dose
Prior art date
Application number
ARP020103852A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR036813(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR036813A1 publication Critical patent/AR036813A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP020103852A 2001-10-17 2002-10-15 Composiciones farmaceuticas AR036813A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124953.1A GB0124953D0 (en) 2001-10-17 2001-10-17 Organic Compounds

Publications (1)

Publication Number Publication Date
AR036813A1 true AR036813A1 (es) 2004-10-06

Family

ID=9924043

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020103852A AR036813A1 (es) 2001-10-17 2002-10-15 Composiciones farmaceuticas
ARP120101574A AR085778A2 (es) 2001-10-17 2012-05-04 Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP120101574A AR085778A2 (es) 2001-10-17 2012-05-04 Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato

Country Status (31)

Country Link
US (3) US20050013859A1 (https=)
EP (1) EP1438040B2 (https=)
JP (2) JP2005508959A (https=)
KR (1) KR100671367B1 (https=)
CN (1) CN1310640C (https=)
AR (2) AR036813A1 (https=)
AT (1) ATE374023T1 (https=)
AU (1) AU2002338897B2 (https=)
BR (1) BR0213355A (https=)
CA (1) CA2460574A1 (https=)
CO (1) CO5390076A1 (https=)
CY (1) CY1107841T1 (https=)
DE (1) DE60222687T3 (https=)
DK (1) DK1438040T4 (https=)
EC (2) ECSP024341A (https=)
ES (1) ES2292819T5 (https=)
GB (1) GB0124953D0 (https=)
HU (1) HU231114B1 (https=)
IL (2) IL160968A0 (https=)
MX (1) MXPA04003636A (https=)
MY (1) MY139206A (https=)
NO (1) NO341804B1 (https=)
NZ (1) NZ532280A (https=)
PE (1) PE20030476A1 (https=)
PL (2) PL415001A1 (https=)
PT (1) PT1438040E (https=)
RU (2) RU2338528C2 (https=)
SI (1) SI1438040T2 (https=)
TW (1) TWI333861B (https=)
WO (1) WO2003032978A1 (https=)
ZA (1) ZA200401977B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US20060069150A1 (en) * 2004-07-20 2006-03-30 Sandor Molnar Processes for preparation of crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20060235009A1 (en) 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
RU2008116578A (ru) * 2005-09-30 2009-11-10 Новартис АГ (CH) Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
US8597679B2 (en) 2005-12-21 2013-12-03 Basf Se Fine-particle crosslinked polyvinylpyrrolidone as tablet disintegrant
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
CN102083410B (zh) 2007-06-06 2013-04-17 巴斯夫欧洲公司 用于制备迅速崩解的片剂的药物制剂
KR20160083132A (ko) 2007-06-06 2016-07-11 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
MX2010001711A (es) * 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
KR20100126465A (ko) * 2008-03-05 2010-12-01 파나세아 바이오테크 리미티드 미코페놀레이트를 포함하는 변형 방출 제약 조성물 및 그것의 방법
US20100010082A1 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
CN102793658A (zh) * 2012-08-23 2012-11-28 无锡福祈制药有限公司 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片
CN103845323B (zh) * 2012-11-30 2018-02-02 重庆华邦制药有限公司 麦考酚酸及其盐肠溶制剂和制备方法
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
CN106727403A (zh) * 2017-01-03 2017-05-31 无锡福祈制药有限公司 一种麦考酚钠肠溶片及其制备方法
WO2018170022A2 (en) * 2017-03-13 2018-09-20 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
AU2019286326A1 (en) * 2018-06-14 2020-12-10 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
RU2723255C2 (ru) * 2018-11-14 2020-06-09 Общество с ограниченной ответственностью "Изварино Фарма" Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
EP4248958A3 (en) * 2021-01-28 2024-01-03 Priothera SAS Methods of treatment with s1p receptor modulators
AU2021424131A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4346790A4 (en) * 2021-05-26 2025-04-16 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN117442580B (zh) * 2023-12-21 2024-04-05 泊诺(天津)创新医药研究有限公司 一种高生物利用度麦考酚钠肠溶片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) † 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
JPS56127093A (en) * 1980-03-10 1981-10-05 Ajinomoto Co Inc Preparation of mycophenolic acid
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4748173A (en) * 1987-01-30 1988-05-31 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions
US5177072A (en) * 1987-01-30 1993-01-05 Syntex (U.S.A.) Inc. Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
EP0670724A1 (en) * 1992-11-24 1995-09-13 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
WO1994012184A1 (en) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
CA2156726C (en) * 1993-02-26 2000-10-17 Paula Denise Davis Bisacodyl dosage form
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
CZ301771B6 (cs) * 1993-10-01 2010-06-16 Syntex (U.S.A.) Llc. Farmaceutický prostredek ve forme suchého granulátu obsahující mofetil mykofenolát nebo kyselinu mykofenolovou a zpusob jeho prípravy
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
EP0724441A1 (en) * 1993-10-19 1996-08-07 The Procter & Gamble Company Picosulphate dosage form
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
JP2002544167A (ja) * 1999-05-10 2002-12-24 ノバルティス アクチエンゲゼルシャフト 有機化合物
HUP9903226A2 (en) * 1999-09-23 2002-08-28 Gyogyszerki Process for producing mycophenolic acid and derivatives thereof
WO2001064931A1 (en) * 2000-02-29 2001-09-07 Biocon India Limited Manufacture and purification of mycophenolic acid
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MXPA04003636A (es) 2004-07-27
NO20041785L (no) 2004-05-03
TWI333861B (en) 2010-12-01
RU2007130786A (ru) 2009-02-20
ATE374023T1 (de) 2007-10-15
US20100210717A1 (en) 2010-08-19
DK1438040T4 (da) 2020-01-27
CN1564684A (zh) 2005-01-12
EP1438040A1 (en) 2004-07-21
GB0124953D0 (en) 2001-12-05
RU2338528C2 (ru) 2008-11-20
ZA200401977B (en) 2006-05-31
CY1107841T1 (el) 2013-06-19
DK1438040T3 (da) 2008-02-04
CN1310640C (zh) 2007-04-18
HK1067861A1 (en) 2005-04-22
RU2381026C2 (ru) 2010-02-10
SI1438040T2 (sl) 2020-02-28
BR0213355A (pt) 2006-05-23
PL234541B1 (pl) 2020-03-31
AU2002338897B2 (en) 2006-10-19
ES2292819T3 (es) 2008-03-16
ECSP024341A (es) 2003-12-01
DE60222687T2 (de) 2008-07-17
ECSP024342A (es) 2003-03-10
MY139206A (en) 2009-08-28
HUP0600451A2 (en) 2006-09-28
IL160968A (en) 2016-04-21
PT1438040E (pt) 2008-01-02
PL415001A1 (pl) 2016-02-29
JP2005508959A (ja) 2005-04-07
IL160968A0 (en) 2004-08-31
PL367738A1 (en) 2005-03-07
US20050013859A1 (en) 2005-01-20
NZ532280A (en) 2007-05-31
DE60222687T3 (de) 2020-03-05
DE60222687D1 (de) 2007-11-08
KR20050037409A (ko) 2005-04-21
ES2292819T5 (es) 2020-05-29
RU2004115332A (ru) 2005-04-20
NO341804B1 (no) 2018-01-22
EP1438040B1 (en) 2007-09-26
US20120237601A1 (en) 2012-09-20
SI1438040T1 (sl) 2008-04-30
CO5390076A1 (es) 2004-04-30
PE20030476A1 (es) 2003-07-30
WO2003032978A1 (en) 2003-04-24
AR085778A2 (es) 2013-10-30
JP2009137996A (ja) 2009-06-25
HU231114B1 (hu) 2020-09-28
KR100671367B1 (ko) 2007-01-19
CA2460574A1 (en) 2003-04-24
EP1438040B2 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
AR036813A1 (es) Composiciones farmaceuticas
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
AR084101A2 (es) Comprimido de carga de droga alta y proceso para su preparacion
GT200100183A (es) Derivados de quinolina y quinazolina.
AR030707A1 (es) 9-ALFA-CLORO-6-ALFA-FLUOR-17-ALFA-HIDROXI-16-METIL-17-BETA-METOXICARBONIL-ANDROST-1,4-DIENOS, UN PROCESO PARA SU PREPARACIoN , COMPOSICION FARMACEUTICA, Y EL USO DEL MISMO PARA LA FABRICACION DE MEDICAMENTO
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
SV1999000049A (es) Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv
BRPI0508833A (pt) formulações galênicas de compostos orgánicos
MX338338B (es) Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias.
BR0207726A (pt) Sais farmacêuticos
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
AR033688A1 (es) Composicion parenteral reconstituible
BR0211198A (pt) Composições farmacêuticas e seu uso
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
MX2007008227A (es) Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos.
CO2026000726A2 (es) Una forma farmacéutica sólida de dosificación bucodispersable de safinamida
SA522441056B1 (ar) مُركّب جديد من كبريتات [2-(داي ميثيل أمينو)-2-فينيل بيوتيل]-3، 4، 5-تراي ميثوكسي بنزوات 4-ميثيل-2h-كرومين-2-ون-7-يل واستخدامه
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
CL2004000810A1 (es) Compuesto derivado de acido hidroxamico de formula definida; composicion farmaceutica que comprende al compuesto y uso del compuesto para preparar medicamentos utiles para tratar trastornos hiperproliferativos.
AR016017A1 (es) Formulaciones farmaceuticas y proceso para su preparacion

Legal Events

Date Code Title Description
FC Refusal